RedHill Biopharma (RDHL) Depreciation & Amortization (CF) (2016 - 2022)
Historic Depreciation & Amortization (CF) for RedHill Biopharma (RDHL) over the last 11 years, with Q4 2022 value amounting to $491000.0.
- RedHill Biopharma's Depreciation & Amortization (CF) rose 935.41% to $491000.0 in Q4 2022 from the same period last year, while for Dec 2023 it was $491000.0, marking a year-over-year decrease of 7701.31%. This contributed to the annual value of $31000.0 for FY2024, which is 9431.19% down from last year.
- Latest data reveals that RedHill Biopharma reported Depreciation & Amortization (CF) of $491000.0 as of Q4 2022, which was up 935.41% from $491000.0 recorded in Q3 2022.
- Over the past 5 years, RedHill Biopharma's Depreciation & Amortization (CF) peaked at $617000.0 during Q2 2022, and registered a low of $22000.0 during Q1 2018.
- Moreover, its 5-year median value for Depreciation & Amortization (CF) was $433000.0 (2020), whereas its average is $342350.0.
- Per our database at Business Quant, RedHill Biopharma's Depreciation & Amortization (CF) crashed by 1538.46% in 2018 and then skyrocketed by 120909.09% in 2019.
- Over the past 5 years, RedHill Biopharma's Depreciation & Amortization (CF) (Quarter) stood at $23000.0 in 2018, then surged by 1000.0% to $253000.0 in 2019, then soared by 86.96% to $473000.0 in 2020, then dropped by 5.07% to $449000.0 in 2021, then increased by 9.35% to $491000.0 in 2022.
- Its last three reported values are $491000.0 in Q4 2022, $491000.0 for Q3 2022, and $617000.0 during Q2 2022.